During the COVID-19 pandemic, the US Food and Drug Administration expanded its use of remote regulatory assessments (RRAs), which allowed the agency to keep its eyes on facilities without investigators having to go on-site.
Based on its experience using RRAs amid the pandemic, the FDA has concluded it should keep the remote
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?